A recent study published in the journal Nature Metabolism has raised concerns about glucosamine supplements commonly used to manage knee pain, suggesting a potential link to accelerated progression of Alzheimer’s disease in susceptible individuals. The research, conducted using genetically predisposed mice, found that glucosamine intake increased the likelihood of developing brain pathology associated with the neurodegenerative disorder. Furthermore, an analysis of health records from people diagnosed with Alzheimer’s indicated that those who consumed glucosamine experienced a more rapid decline in their condition.

Glucosamine, often combined with chondroitin sulfate, is widely used by individuals suffering from osteoarthritis and other joint issues to alleviate pain and improve mobility. One long-term user reported that while off the supplement, their knee pain intensified, but upon resuming glucosamine and chondroitin, recovery time after skiing and overall pain levels improved noticeably. The individual also employed a variety of complementary remedies, including natural anti-inflammatory agents such as bromelain, boswellia, turmeric, hyaluronic acid, celery seed capsules, and fish oil, to manage symptoms.

Despite the observed benefits in joint health and pain relief, experts urge caution, particularly for those with existing cognitive impairments or heightened risk factors for Alzheimer’s disease. The study’s authors emphasize that the increased risk may not extend to the general population but recommend exploring alternative treatments and supplements for managing joint symptoms where appropriate.

In an unrelated health topic, researchers have investigated the reasons mosquitoes selectively bite some people more than others. Findings indicate that the scent produced by skin microbes plays a significant role in mosquito attraction or deterrence. Some individuals report rarely being bitten, suggesting their unique skin microbiome composition may influence mosquito behavior, highlighting potential avenues for developing new repellents.

Separately, concerns have been raised regarding the long-term use of sedating medications for sleep disorders. One case involved a person relying on a combination of zolpidem (Ambien), trazodone, and a multi-ingredient cold remedy containing doxylamine to achieve sleep. Medical experts caution that this combination of multiple sedatives can lead to significant next-day drowsiness and may not be a safe or effective long-term strategy. They note that while trazodone is sometimes prescribed off-label for insomnia, it has not been officially approved for this use and, combined with other sedatives, may increase adverse effects.

These findings underscore the importance of ongoing evaluation of common supplements and medications, weighing their benefits against potential risks, especially among vulnerable populations. Health professionals encourage patients to consult with providers when considering or currently using such treatments.